Genome.One.
The future transformed.

Genome.One provides clinical Whole Genome Sequencing to answer life’s biggest health questions – enhancing the lives of patients, families and communities across the world.    

Backed by the pioneering excellence of the Garvan Institute of Medical Research, we make genomic break-throughs accessible to all, for the benefit of all.

How do we do it >

Genome.One is a wholly owned subsidiary of the Garvan Institute of Medical Research. We provide clinical Whole Genome Sequencing to answer life’s biggest health questions – enhancing the lives of patients, families and communities across the world.

Genome.one services

The Purpose Behind the Science of Genomics

We understand that medicine is all about the search for answers. Our job, although not simple, is clear. To make that search more efficient, more productive and more accurate. That’s what Whole Genome Sequencing (WGS) with Genome.One is all about. WGS will provide you and your patients access to this new genomics technology, to help with greater accuracy and speed of diagnosis.

How do we do it >

The People Behind the Diagnoses

As a wholly owned subsidiary of the Garvan Institute of Medical Research, we are backed by pioneering excellence. The Genome.One laboratory is accredited by NATA for Medical Testing, and meets with AS ISO 15189 requirements.

Meet the team >

The Benefits of Whole Genome Sequencing

WGS provides you and your patients with access to all of their genetic information at the same time, which can be analysed and interpreted now for your initial request and whenever you and your patients require it in the future. It is therefore a once in a lifetime sequencing test and the information that is generated provides potential benefits at many different life stages.

In terms of immediate and practical advantages, here’s what you can expect.

1

Broad coverage

Minimum average coverage of 30x with 96.6% of protein-coding bases consistently covered (≥15x) including splice sites.

Greater detail

Identify protein-coding variants that can be missed by whole exome sequencing.

2

3

Higher diagnostic yield

Delivering 20–30% higher diagnosis rates (up to 60% in some disease areas) than most gene panels or whole exome sequencing in a turn-around time of 8–12 weeks*.

* Turnaround time (“TAT”) starts when all samples have been received by the laboratory and all necessary documentation and payment requirements have been completed. Specimen with urgent priority can be expedited: please contact us to arrange this.